Address
Email address
Phone number
Website
https://www.icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
Icosagen AS
Registry code
10565884
VAT number
EE100573055
Type
AS - Joint Stock Company
Status
Registered
Foundation date
27.08.1999 (25)
Financial year
01.01-31.12
Capital
192 448.00 €
Activity
72191 - Other research and experimental development on natural sciences and engineering 96099 - Other service activities 72111 - Research and experimental development on biotechnology
14 469 106 €
2 489 374 €
17%
2 934 €
(estimate is approximate)
22 900 302 €
166
Submitted
No tax arrears
11%
8%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Amplikon OÜ 12860392 | 96% - 184 838.40 EUR | - | - | Shareholder |
| Mart Ustav 16.07.1949 (75) | - | Board member | Indirect ownership | Founder |
| Mart Ustav 08.07.1986 (38) | - | Board member | - | |
| Ene Talpsep 25.03.1953 (71) | - | - | Direct ownership | Board member |
| Richard Villems 28.11.1944 (79) | - | - | - | Board member |
| Ain Laving 16.06.1947 (77) | - | - | - | Founder |
| Elve Raukas 27.06.1956 (68) | - | - | - | Founder |
| Marika Mikelsaar 12.11.1938 (86) | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| ICO Park OÜ 12401945 | 100% - 2 502.00 EUR | - | - | Founder |
| Icosagen Cell Factory OÜ 11107818 | 100% - 11 504.00 EUR | - | - | Founder |
| OÜ Icosagen Toxicology Services 12402287 | 40% - 1 000.00 EUR | - | - | Founder |
| SYNLAB Eesti OÜ 11107913 | - | - | - | Founder |
| aktsiaselts Biotehnoloogia Park Kinnisvara 10834232 | - | - | - | Founder |
| 2019 30.06.2020 | 2020 29.10.2021 | 2021 30.06.2022 | 2022 19.06.2023 | 2023 11.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 1 096 550 € | 8 736 977 € | 13 150 460 € | 14 764 667 € | 14 469 106 € |
| Net profit (loss) for the period | 139 232 € | 2 848 535 € | 6 700 963 € | 6 155 891 € | 2 489 374 € |
| Profit Margin | 13% | 33% | 51% | 42% | 17% |
| Current Assets | 1 189 275 € | 5 988 725 € | 12 635 927 € | 15 027 550 € | 8 444 444 € |
| Fixed Assets | 1 522 507 € | 4 101 103 € | 4 629 033 € | 11 032 326 € | 24 104 249 € |
| Total Assets | 2 711 782 € | 10 089 828 € | 17 264 960 € | 26 059 876 € | 32 548 693 € |
| Current Liabilities | 285 138 € | 2 219 292 € | 1 881 507 € | 4 096 883 € | 5 958 987 € |
| Non Current Liabilities | 33 918 € | 601 110 € | 1 406 474 € | 1 706 657 € | 3 689 404 € |
| Total Liabilities | 319 056 € | 2 820 402 € | 3 287 981 € | 5 803 540 € | 9 648 391 € |
| Share Capital | 192 448 € | 192 448 € | 192 448 € | 192 448 € | 192 448 € |
| Equity | 2 392 726 € | 7 269 426 € | 13 976 979 € | 20 256 336 € | 22 900 302 € |
| Employees | 63 | 69 | 92 | 131 | 166 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 755 727.08 € | 213 876.25 € | 158 927.07 € | 32 |
| 2023 Q4 | 493 171.14 € | 146 801.14 € | 106 943.01 € | 31 |
| 2023 Q3 | 644 958.01 € | 167 489.75 € | 108 939.92 € | 32 |
| 2023 Q2 | 312 229.78 € | 113 820.42 € | 106 726.26 € | 31 |
| 2023 Q1 | 1 253 221.81 € | 136 474.36 € | 138 949.78 € | 33 |
| 2022 Q4 | 321 851.17 € | 89 605.59 € | 90 365.87 € | 30 |
| 2022 Q3 | 376 835.42 € | 91 642.1 € | 93 200.11 € | 31 |
| 2022 Q2 | 316 313.26 € | 86 231.84 € | 84 149.06 € | 31 |
| 2022 Q1 | 747 059.21 € | 115 928.44 € | 122 481.58 € | 30 |
| 2021 Q4 | 1 503 788.96 € | 66 955.7 € | 69 694.43 € | 31 |
| 2021 Q3 | 688 896.47 € | 63 119.21 € | 72 630.12 € | 31 |
| 2021 Q2 | 700 350.46 € | 74 917.16 € | 60 313.95 € | 32 |
| 2021 Q1 | 542 830.46 € | 85 833.62 € | 73 644.84 € | 23 |
| 2020 Q4 | 747 667.97 € | 83 331.75 € | 61 866.77 € | 22 |
| 2020 Q3 | 733 661.32 € | 67 866.8 € | 59 595.17 € | 27 |
| 2020 Q2 | 611 750.64 € | 72 848.69 € | 49 196.29 € | 24 |
| 2020 Q1 | 294 857.56 € | 74 072.7 € | 59 557.54 € | 23 |
